Gene Liau, EVP Research & Preclinical Development at Stoke Therapeutics, Inc. (STOK), sold 7,500 shares at $30.00 ($225K) on 2020-05-22, disclosed to the SEC on 2020-05-26.
Open-market sale of $225k STOK by EVP Research & Preclinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| STOK | SELL | 2020-10-13 | $66K | — | Filing → |
| STOK | SELL | 2020-06-03 | $1.0M | — | Filing → |